Published online before print June 1, 2004, doi: 10.1161/01.CIR.0000129318.79570.84
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2004;109:2850-2856.)
© 2004 American Heart Association, Inc.
Clinical Investigation and Reports |
Relations of Plasma Matrix Metalloproteinase-9 to Clinical Cardiovascular Risk Factors and Echocardiographic Left Ventricular Measures
The Framingham Heart Study
From the Framingham Heart Study (J.S., J.C.E., E.J.B., D.L., M.G.L., P.S., P.W.F.W., R.S.V.), Framingham, Mass; the National Heart, Lung, and Blood Institute (D.L.); and the Department of Preventive Medicine (E.J.B., D.L., R.S.V.), Cardiology Section (E.J.B., D.B.S., W.S.C., R.S.V.), and the Myocardial Biology Unit (D.B.S., D.A.S., W.S.C.), Boston University School of Medicine, Boston, Mass.
Correspondence to Ramachandran S. Vasan, MD, The Framingham Heart Study, 73 Mt Wayte Ave, Framingham, MA 01702–5803. E-mail vasan{at}bu.edu
Received October 24, 2003; de novo received December 11, 2003; revision received February 20, 2004; accepted February 25, 2004.
Background— Plasma levels of matrix metalloproteinase-9 (MMP-9), a key determinant of extracellular matrix degradation, are increased in heart failure and in acute coronary syndromes. We investigated cross-sectional relations of plasma MMP-9 to vascular risk factors and echocardiographic left ventricular (LV) measurements.
Methods and Results— We studied 699 Framingham Study participants (mean age, 57 years; 58% women), free of heart failure and previous myocardial infarction, who underwent routine echocardiography. We examined sex-specific distributions of LV internal dimensions (LVEDD) and wall thickness (LVWT) and sampled persons with both LVEDD and LVWT below the sex-specific median (referent, n=299), with increased LVEDD (LVEDD 
90th percentile, n=204) and increased LVWT (LVWT 90th percentile, n=221) in a 3:2:2 ratio. Plasma MMP-9 was detectable in 138 persons (20%). In multivariable models, increasing heart rate (OR per SD, 1.41; 95% CI, 1.17 to 1.71) and antihypertensive treatment (OR, 1.63; 95% CI, 1.06 to 2.50) were key clinical correlates of detectable plasma MMP-9. In multivariable-adjusted models, detectable plasma MMP-9 was associated with increased LVEDD (OR, 2.84; 95% CI, 1.13 to 7.11), increased LVWT (OR, 2.54; 95% CI, 1.00 to 6.46), and higher LV mass (P=0.06) in men but not in women (OR for increased LVEDD, 1.37; 95% CI, 0.54 to 3.46; for increased LVWT, 0.99; 95% CI, 0.39 to 2.52; P=0.59 for LV mass).
Conclusions— In our community-based sample, detectable plasma MMP-9 levels were associated with increased LV diastolic dimensions and increased wall thickness in men. These observations indicate that plasma MMP-9 level may be a marker for cardiac extracellular matrix degradation, a process involved in LV remodeling.
Key Words: heart failure • hypertrophy • metalloproteinases • remodeling • echocardiography
This article has been cited by other articles:
 |
|
 |
|
  N. Makino, T. Maeda, J.-i. Oyama, Y. Higuchi, and K. Mimori Improving insulin sensitivity via activation of PPAR-{gamma} increases telomerase activity in the heart of OLETF rats Am J Physiol Heart Circ Physiol, December 1, 2009; 297(6): H2188 - H2195. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Dhingra, M. J. Pencina, P. Schrader, T. J. Wang, D. Levy, K. Pencina, D. A. Siwik, W. S. Colucci, E. J. Benjamin, and R. S. Vasan Relations of Matrix Remodeling Biomarkers to Blood Pressure Progression and Incidence of Hypertension in the Community Circulation, March 3, 2009; 119(8): 1101 - 1107. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Zavadzkas, R. A. Plyler, S. Bouges, C. N. Koval, W. T. Rivers, C. U. Beck, E. I. Chang, R. E. Stroud, R. Mukherjee, and F. G. Spinale Cardiac-restricted overexpression of extracellular matrix metalloproteinase inducer causes myocardial remodeling and dysfunction in aging mice Am J Physiol Heart Circ Physiol, October 1, 2008; 295(4): H1394 - H1402. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. G. Spinale, C. N. Koval, A. M. Deschamps, R. E. Stroud, and J. S. Ikonomidis Dynamic Changes in Matrix Metalloprotienase Activity Within the Human Myocardial Interstitium During Myocardial Arrest and Reperfusion Circulation, September 30, 2008; 118(14_suppl_1): S16 - S23. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Kelly, S. Q. Khan, M. Thompson, G. Cockerill, L. L. Ng, N. Samani, and I. B. Squire Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction Eur. Heart J., September 1, 2008; 29(17): 2116 - 2124. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Frantz, S. Stork, K. Michels, M. Eigenthaler, G. Ertl, J. Bauersachs, and C.E. Angermann Tissue inhibitor of metalloproteinases levels in patients with chronic heart failure: An independent predictor of mortality Eur J Heart Fail, April 1, 2008; 10(4): 388 - 395. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Yang, Y. Ma, W. Han, J. Li, Y. Xiang, F. Liu, X. Ma, J. Zhang, Z. Fu, Y.-D. Su, et al. Age-related differences in postinfarct left ventricular rupture and remodeling Am J Physiol Heart Circ Physiol, April 1, 2008; 294(4): H1815 - H1822. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Cheung, D. Marchant, E. K.-Y. Walker, Z. Luo, J. Zhang, B. Yanagawa, M. Rahmani, J. Cox, C. Overall, R. M. Senior, et al. Ablation of Matrix Metalloproteinase-9 Increases Severity of Viral Myocarditis in Mice Circulation, March 25, 2008; 117(12): 1574 - 1582. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Timmers, J. P.G. Sluijter, J. K. van Keulen, I. E. Hoefer, M. G.J. Nederhoff, M.-J. Goumans, P. A. Doevendans, C. J.A. van Echteld, J. A. Joles, P. H. Quax, et al. Toll-Like Receptor 4 Mediates Maladaptive Left Ventricular Remodeling and Impairs Cardiac Function After Myocardial Infarction Circ. Res., February 1, 2008; 102(2): 257 - 264. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. van de Wal, P. van der Harst, W. B. Gerritsen, F. van der Horst, T. H. Plokker, R. T Gansevoort, W. H van Gilst, and A. A Voors Plasma matrix metalloproteinase-9 and ACE-inhibitor-induced improvement of urinary albumin excretion in non-diabetic, microalbuminuric subjects Journal of Renin-Angiotensin-Aldosterone System, December 1, 2007; 8(4): 177 - 180. [Abstract] [PDF]
|
|
|
|
 |
|
 F. G. Spinale Myocardial Matrix Remodeling and the Matrix Metalloproteinases: Influence on Cardiac Form and Function Physiol Rev, October 1, 2007; 87(4): 1285 - 1342. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Ernens, D. Rouy, E. Velot, Y. Devaux, and D. R. Wagner Adenosine Inhibits Matrix Metalloproteinase-9 Secretion By Neutrophils: Implication of A2a Receptor and cAMP/PKA/Ca2+ Pathway Circ. Res., September 15, 2006; 99(6): 590 - 597. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Webb, D. D. Bonnema, S. H. Ahmed, A. H. Leonardi, C. D. McClure, L. L. Clark, R. E. Stroud, W. C. Corn, L. Finklea, M. R. Zile, et al. Specific Temporal Profile of Matrix Metalloproteinase Release Occurs in Patients After Myocardial Infarction: Relation to Left Ventricular Remodeling Circulation, September 5, 2006; 114(10): 1020 - 1027. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Sato, K. Aonuma, K. Imanaka-Yoshida, T. Yoshida, M. Isobe, D. Kawase, N. Kinoshita, Y. Yazaki, and M. Hiroe Serum Tenascin-C Might Be a Novel Predictor of Left Ventricular Remodeling and Prognosis After Acute Myocardial Infarction J. Am. Coll. Cardiol., June 6, 2006; 47(11): 2319 - 2325. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Tazaki, K. Minoguchi, T. Yokoe, K. T. R. Samson, H. Minoguchi, A. Tanaka, Y. Watanabe, and M. Adachi Increased Levels and Activity of Matrix Metalloproteinase-9 in Obstructive Sleep Apnea Syndrome Am. J. Respir. Crit. Care Med., December 15, 2004; 170(12): 1354 - 1359. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. H. Messerli TIMPs, MMPs and cardiovascular disease Eur. Heart J., September 1, 2004; 25(17): 1475 - 1476. [Full Text] [PDF]
|
|